


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 3220-67852	SERIAL No. 09/822,376		
INFORMATION DISCLOSURE STATEMENT			APPLICANT Borch, et al.			
			FILING DATE March 30, 2001	GROUP 1645		
<span style="font-size: 2em; font-weight: bold;">RECEIVED</span> <span style="font-size: 1em; border: 1px solid black; padding: 2px;">SEARCHED</span> <span style="font-size: 1em; border: 1px solid black; padding: 2px;">INDEXED</span> <span style="font-size: 1em; border: 1px solid black; padding: 2px;">MAILED</span> <span style="font-size: 1em; border: 1px solid black; padding: 2px;">OCT 18 2001</span> <span style="font-size: 1em; border: 1px solid black; padding: 2px;">USPTO</span>						
U.S. PATENT DOCUMENTS						
*Examiner Initial		Document Number	Date	Name	Class	Subclass
<i>JL</i>	AA	5,472,956	Dec. 5, 1995	Borch et al.	514	95
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
FOREIGN PATENT DOCUMENTS						
		Document Number	Date	Country	Class	Subclass
<i>JL</i>	AL	WO 93/06120	04/01/93	PCT		
	AM					
	AN					
	AO					
	AP					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)						
<i>JL</i>	AR	"The Synthesis of O-monosaccharidyl-methoxycarbonyl-phosphonamides by Arbuzov reaction" R.Y. Chen, et al. Chinese Chemical Letters., vol. 6, no. 1, 1995, pages 23-26.				
<i>JL</i>	AS	"Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants For In Vitro Activity and QSAR" A.Q. Siddiqui, et al., Journal of Medicinal Chemistry, Vol 42, No. 20, 1999, pgs 4122-4128.				
<i>JL</i>	AT	"Phosphoramidates as Potent Prodrugs of Anti-HIV Nucleotides: Studies in the Amino Region," C. McGuigan, et al. Antiviral Chemistry & Chemotherapy, Vol 7, No. 1, 1996, pgs 31-36.				
Examiner	<i>David L. Ettinger</i>			Date Considered	4/13/04	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.      Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>						

RECEIVED  
OCT 18 2001  
TECH CENTER 1600  
2900

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. 3220-67852	SERIAL No. 09/822,376		
INFORMATION DISCLOSURE STATEMENT				APPLICANT Borch, et al.			
				FILING DATE March 30, 2001	GROUP 1645		
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	BL						
	BM						
	BN						
	BO						
	AP						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BR	"Design and Synthesis of Novel Nucleotide Prodrugs," Caren F. Meyers, et al., American Association for Cancer Research 2000, Abstract No. 100710					
	BS						
	AT						
Examiner					Date Considered <u>4/13/04</u>		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.            Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							